Oruka Therapeutics, Inc
Price
OptionsOpen the Sheet →FilingsNewest: 424B5, Offering prospectusAug 28 →InsidersNo open-market buys. 6 insiders sold $13.7M, 48 of 55 sales on a 10b5-1 plan.→HoldersFMR 14.8%BlackRock 8.2%Venrock Adviser 6.8%→Financing →PeersClosest companies: APGE, ERAS, JANX→
From the filings
Figures
- Net income
- −$132.9Mlast 12 months
- Operating cash flow
- −$90.9Mlast 12 months
- Cash and equivalents
- $268.5Mat the last balance sheet
- Shares outstanding
- 61.1M shareson issue